[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemialymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemialymphoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100363604","post-authorization-safety-study-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-treated-with-mogamulizumab-100363604",false,"NCT04014374","Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab","Inclusion Criteria:\n\n* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)\n* Adults ≥18 years of age with either CTCL or ATLL;\n* AlloHCT performed from January 2012 onward.\n\nExclusion Criteria:\n\n• Patients without consent for research.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","2 Years","OBSERVATIONAL","This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.",[24,25,26],"Leukemia\u002FLymphoma","Cutaneous T Cell Lymphoma","ATLL","RECRUITING","2024-07-23",{"date":30,"type":31},"2024-07-24","ACTUAL",{"date":33,"type":31},"2019-09-10",{"date":35,"type":19},"2030-02",{"name":37,"class":38},"Kyowa Kirin, Inc.","INDUSTRY"]